Literature DB >> 19654105

Thymidine kinase 1 and thymidine phosphorylase expression in non-small-cell lung carcinoma in relation to angiogenesis and proliferation.

J Scott Brockenbrough1, Janice K Morihara, Stephen E Hawes, Joshua E Stern, Janet S Rasey, Linda W Wiens, Qinghua Feng, Hubert Vesselle.   

Abstract

The thymidine salvage pathway enzymes thymidine kinase 1 (TK1) and thymidine phosphorylase (TP) compete for thymidine as a substrate and catalyze opposing synthetic and catabolic reactions that have been implicated in the control of proliferation and angiogenesis, respectively. We investigated the relationship between the expression of TK1 and TP as they relate to proliferation (Ki-67 labeling index) and angiogenesis (Chalkley count of CD31-stained blood vessels) in a series of 110 non-small-cell lung cancer (NSCLC) tumors from patients prospectively enrolled in an imaging trial. TK1 and TP exhibited similar patterns of immunohistochemical distribution, in that each was found in both the nucleus and the cytoplasm of tumor cells. Each enzyme exhibited a significant positive correlation between its levels of nuclear and cytoplasmic expression. A significant positive correlation between TK1 expression and the Ki-67 labeling index (r = 0.53, p<0.001) was observed. TP was significantly positively correlated with Chalkley scoring of CD31 staining in high vs low Chalkley scoring samples (mean TP staining of 115.8 vs 79.9 scoring units, p<0.001), respectively. We did not observe a substantial inverse correlation between the TP and TK1 expression levels in the nuclear compartment (r = -0.17, p=0.08). Tumor size was not found to be associated with TK1, TP, Ki-67, or Chalkley score. These findings provide additional evidence for the role of thymidine metabolism in the complex interaction of proliferation and angiogenesis in NSCLC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19654105      PMCID: PMC2762886          DOI: 10.1369/jhc.2009.952804

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  89 in total

Review 1.  Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us.

Authors:  Lynn Hlatky; Philip Hahnfeldt; Judah Folkman
Journal:  J Natl Cancer Inst       Date:  2002-06-19       Impact factor: 13.506

2.  In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors.

Authors:  Hubert Vesselle; John Grierson; Mark Muzi; Jeffrey M Pugsley; Rodney A Schmidt; Peter Rabinowitz; Lanell M Peterson; Eric Vallières; Douglas E Wood
Journal:  Clin Cancer Res       Date:  2002-11       Impact factor: 12.531

3.  Molecular basis for the inhibition of hypoxia-induced apoptosis by 2-deoxy-D-ribose.

Authors:  Ryuji Ikeda; Tatsuhiko Furukawa; Masaki Kitazono; Kenji Ishitsuka; Hiroshi Okumura; Ayako Tani; Tomoyuki Sumizawa; Misako Haraguchi; Masaharu Komatsu; Hiroshi Uchimiya; Xiao-Qin Ren; Toshiro Motoya; Katsushi Yamada; Shin-ichi Akiyama
Journal:  Biochem Biophys Res Commun       Date:  2002-03-08       Impact factor: 3.575

4.  Expression of genes involved in chemoresistance, proliferation and apoptosis in clinical samples of renal cell carcinoma and correlation with clinical outcome.

Authors:  Stephane Oudard; Cecile Levalois; Jean-Marie Andrieu; Joelle Bougaran; Pierre Validire; Nicolas Thiounn; Marie-France Poupon; Emmanuelle Fourme; Sylvie Chevillard
Journal:  Anticancer Res       Date:  2002 Jan-Feb       Impact factor: 2.480

5.  Suppression of thymidine phosphorylase-mediated angiogenesis and tumor growth by 2-deoxy-L-ribose.

Authors:  Hiroshi Uchimiya; Tatsuhiko Furukawa; Masahiro Okamoto; Yuichi Nakajima; Shigeto Matsushita; Ryuji Ikeda; Takenari Gotanda; Misako Haraguchi; Tomoyuki Sumizawa; Mayumi Ono; Michihiko Kuwano; Tamotsu Kanzaki; Shin-ichi Akiyama
Journal:  Cancer Res       Date:  2002-05-15       Impact factor: 12.701

6.  Thymidine phosphorylase expression in gallbladder adenocarcinomas.

Authors:  Alexandra Giatromanolaki; Efthimios Sivridis; Constantinos Simopoulos; Alexandros Polychronidis; Kevin C Gatter; Adrian L Harris; Michael I Koukourakis
Journal:  Int J Surg Pathol       Date:  2002-07       Impact factor: 1.271

7.  A comparative study: immunohistochemical detection of cytosolic thymidine kinase and proliferating cell nuclear antigen in breast cancer.

Authors:  Yongrong Mao; Jianping Wu; Naining Wang; Lanxiang He; Chuanjing Wu; Qimin He; Sven Skog
Journal:  Cancer Invest       Date:  2002       Impact factor: 2.176

8.  Mechanisms by which tumor cells and monocytes expressing the angiogenic factor thymidine phosphorylase mediate human endothelial cell migration.

Authors:  Kylie A Hotchkiss; Anthony W Ashton; Robert S Klein; Michelle L Lenzi; Geng Hui Zhu; Edward L Schwartz
Journal:  Cancer Res       Date:  2003-01-15       Impact factor: 12.701

9.  Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells.

Authors:  Janet S Rasey; John R Grierson; Linda W Wiens; Pamella D Kolb; Jeffrey L Schwartz
Journal:  J Nucl Med       Date:  2002-09       Impact factor: 10.057

10.  Thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma: relationship between histological parameters and chemosensitivity to 5-fluorouracil.

Authors:  Yasuhiro Hirano; Tatsuya Takayama; Shinji Kageyama; Tomomi Ushiyama; Kazuo Suzuki; Kimio Fujita
Journal:  Eur Urol       Date:  2003-01       Impact factor: 20.096

View more
  10 in total

1.  High thymidine kinase 1 (TK1) expression is a predictor of poor survival in patients with pT1 of lung adenocarcinoma.

Authors:  Yan Xu; Qun-Li Shi; Henghui Ma; Hangbo Zhou; Zhenfeng Lu; Bo Yu; Xiaojun Zhou; Staffan Eriksson; Ellen He; Sven Skog
Journal:  Tumour Biol       Date:  2011-12-06

2.  The Association of Serum Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Thymidine Kinase, and Tissue Polypeptide Specific Antigen with Outcomes of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab: a Retrospective Study.

Authors:  Ondrej Fiala; Jindrich Finek; Tomas Buchler; Vit Martin Matejka; Lubos Holubec; Jana Kulhankova; Zbynek Bortlicek; Vaclav Liska; Ondrej Topolcan
Journal:  Target Oncol       Date:  2015-12       Impact factor: 4.493

Review 3.  Thymidine Phosphorylase in Cancer; Enemy or Friend?

Authors:  Yasir Y Elamin; Shereen Rafee; Nemer Osman; Kenneth J O Byrne; Kathy Gately
Journal:  Cancer Microenviron       Date:  2015-08-23

4.  Evaluation of [18F]Fluorothymidine as a Biomarker for Early Therapy Response in a Mouse Model of Colorectal Cancer.

Authors:  Sara Rapic; Christel Vangestel; Jeroen Verhaeghe; David Thomae; Patrick Pauwels; Tim Van den Wyngaert; Steven Staelens; Sigrid Stroobants
Journal:  Mol Imaging Biol       Date:  2017-02       Impact factor: 3.488

5.  Thymidine kinase 1 is a better prognostic marker than Ki-67 for pT1 adenocarcinoma of the lung.

Authors:  Yan Xu; Biao Liu; Qun-Li Shi; Pei-Lin Huang; Xiao-Jun Zhou; Heng-Hui Ma; Zhen-Feng Lu; Yu Bo; Staffan Eriksson; Ellen He; Sven Skog
Journal:  Int J Clin Exp Med       Date:  2014-08-15

6.  Regulation and functional contribution of thymidine kinase 1 in repair of DNA damage.

Authors:  Yen-Ling Chen; Staffan Eriksson; Zee-Fen Chang
Journal:  J Biol Chem       Date:  2010-06-16       Impact factor: 5.157

7.  Thymidine kinase 1 as a diagnostic tumor marker is of moderate value in cancer patients: A meta-analysis.

Authors:  Yanqun Xiang; Hua Zeng; Xiang Liu; Hui Zhou; Ling Luo; Chaohui Duan; Xiaohong Luo; Haiyan Yan
Journal:  Biomed Rep       Date:  2013-05-28

8.  Severe hypertriglyceridaemia during treatment with capecitabine.

Authors:  L Javot; D Spaëth; J Scala-Bertola; N Gambier; N Petitpain; P Gillet
Journal:  Br J Cancer       Date:  2011-03-08       Impact factor: 7.640

9.  Anticancer activity of a thymidine quinoxaline conjugate is modulated by cytosolic thymidine pathways.

Authors:  Qiong Wei; Haijuan Liu; Honghao Zhou; Dejun Zhang; Zhiwei Zhang; Qibing Zhou
Journal:  BMC Cancer       Date:  2015-03-21       Impact factor: 4.430

10.  Synthesis, Molecular Docking, and Preclinical Evaluation of a New Succinimide Derivative for Cardioprotective, Hepatoprotective and Lipid-Lowering Effects.

Authors:  Muhammad Imran Qayyum; Sami Ullah; Umer Rashid; Abdul Sadiq; Mater H Mahnashi; Osama M Alshehri; Mohammed M Jalal; Khalid J Alzahrani; Ibrahim F Halawani
Journal:  Molecules       Date:  2022-09-21       Impact factor: 4.927

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.